header logo image


Page 8«..78910..2030..»

Archive for February, 2020

Predicting Immunotherapy Success – BSA bureau

Tuesday, February 25th, 2020

Overexpression of certain immunoproteasome subunits in melanoma are tied to anti-cancer immune activity

One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy.

Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.

For Prof. Yardena Samuels and her research group partnered with Prof. Eytan Ruppins lab in the National Institutes of Health (USA), basing their research on the understanding that learning to predict which treatments are most likely to work is the first step to creating a personalized approach to curing cancer. The focus of their work is melanoma a collection of skin cancers that are often hard to treat, and which may be made up of varied tumor cells containing hundreds of different mutations. A certain percentage of melanomas have in recent years been successfully treated with immunotherapy drugs known as checkpoint inhibitors, which work by removing internal obstacles that trip up the bodys own immune system and keep it from attacking the cancer. Unfortunately, for others, these drugs remain ineffective.

To understand the differences in response between different people, the research team, led by postdoctoral fellow Dr. Shelly Kalaora in Samuels group and Joo Sang Li in the Ruppin group, first analyzed data from 470 melanoma patients that has been made available in the Cancer Genome Atlas (TCGA). They were particularly interested in differences in survival rates of patients in whom particular subunits of immunoproteasomes are overexpressed compared to those with low expression of these subunits. These are a variation on the proteasome subunits normally expressed in most cells (except for immune cells). Proteasomes are protein complexes that function as cutters, reducing long proteins to short pieces called peptides. These peptides are later presented on the cells surface by molecules called human leucocyte antigens (HLA). HLA peptides are basically bits of information small molecules displayed on the outsides of cells that report about new threats that the immune system needs to assess and address.

The immunoproteasome is assembled out of altered subunits and thus produces a unique collection of HLA peptides. The team thought that a particular change and overexpression in the HLA peptide repertoire might result in better recognition of the tumor cells by the immune system and thus better elimination of cancer cells.

To test this idea, the researchers cultured lines of tumor cells from melanoma patients in which they overexpressed the immunoproteasome subunits and identified the HLA peptides presented in each situation. By testing the response of the immune cells from the same patients, they showed that the newly formed HLA peptides were indeed more reactive compared to the HLA peptides presented by cells without this overexpression.

Could two subunits the research identified in particular and the unique HLA-bound peptides these produce be a predictor of immunotherapy success? The experiments showed that in tumor cells in which the subunits were overexpressed, the various immune system components that directly fight the cancer were more prevalent and more active than average. Indeed, looking back at the details of cancer patients in the database, the team reported that the expression levels of the two subunits were excellent predictors of the outcome better than the tumor mutational burden, a biomarker that is currently used in the clinic. The researchers in Samuelss and Ruppins lab suggest that expression of the immunoproteasome may be used as a biomarker for predicting better outcomes in melanoma and, together with mutational load testing, may improve patient matching to currently available immunotherapy.

Prof. Yardena Samuels is the head of the EKARD Institute for Cancer Diagnosis Research; and head of the Weizmann-Brazil Tumor Bank. Her research is also supported by the Laboratory in the name of M.E.H Fund established by Margot and Ernst Hamburger; the Green Family Charitable Foundation; the Wagner-Braunsberg Family Melanoma Research Fund; the Jean-Jacques Brunschwig Fund for the Molecular Genetics of Cancer; the Comisaroff Family Trust; the Rising Tide Foundation; the Fundacin Ramn Areces; the Meyer Henri Cancer Endowment; Ted and Sylvia Quint; Jean Jacques Roboh; and the European Research Council. Prof Samuels is the incumbent of the Knell Family Professorial Chair.

Original post:
Predicting Immunotherapy Success - BSA bureau

Read More...

Oncology Start-up OncoLens Named to Top 10 List of Innovative Technology Companies in Georgia – PR Web

Tuesday, February 25th, 2020

ATLANTA (PRWEB) February 24, 2020

OncoLens is pleased to announce it has been named one of the Top 10 Innovative Technology Companies in Georgia by the Technology Association of Georgia (TAG).

Oncology focused, OncoLens is a SaaS-based tumor board platform to help cancer centers connect members of their care teams, as they make treatment decisions for their patients. Centers can increase their referrals and streamline workflows. They can also reduce tumor board prep time by 90% and time to initiate patient treatment from 14 to 2 days.

OncoLens utilizes some of the latest technologies in conjunction with its own proprietary algorithms to identify treatment options for the cancer patient, said Anju Mathew, Co-Founder and CEO, OncoLens. The platform identifies clinical trials, evidence-based guidelines and personalized treatment options based on the tumor genotype. These options are proposed to the multi-disciplinary cancer care team to help them make the best decision possible for the cancer patient.

Better patient outcomes can result from OncoLens robust functionality. Cancer care teams can engage research staff early and automatically screen cases available for clinical trials. Physicians are able to access real time data for clinical decision-making, while the system works in the background to facilitate data/document collection, including EMR clinical data, laboratory and molecular genetics test results and radiology images. The platform also supports regulatory reporting for associations such as the Commission on Cancer (CoC), NAPBC and NAPRC.

The Top 10 were selected from TAGs Top 40 Innovative Technology Companies competition for showing the highest degree of innovation, the broadest scope and financial impact of their innovations, and the greatest effect of such innovation in promoting Georgia's technology industry throughout the U.S. and globally.

As a Top 10 honoree, OncoLens will present at The Summit, hosted by TAG, March 3-4, at Cobb Galleria, in Atlanta. It is Georgias largest technology showcase. We look forward to sharing the future of innovative cancer care at TAGs event, said Mathew.

###About OncoLens OncoLens develops technologies that improve cancer treatment planning, simplify tumor board management, facilitate survivorship care planning, and automate accreditations and quality reporting through an intelligent workflow engine that streamlines business processes and enables more informed clinical decision-making. For more information, visit http://www.oncolens.com.

Share article on social media or email:

Follow this link:
Oncology Start-up OncoLens Named to Top 10 List of Innovative Technology Companies in Georgia - PR Web

Read More...

Global Molecular Diagnostic Product Market Analysis And Forecast To 2026 By Recent Trends, Developments In Manufacturing Technology And Regional…

Tuesday, February 25th, 2020

Reportspedia.com in its latest market intelligence study, finds that the Global Molecular Diagnostic Product Market registered a value of ~US$ xx Mn/Bn in 2019 and is observed to grow at CAGR of xx% during the estimative period 2020-2026. In terms of product type, segments holds the significant share, in terms of end use. All the consumption trends and adoption patterns of the Molecular Diagnostic Product are covered in the report.

Download Exclusive Sample of Molecular Diagnostic Product Markets Premium Report at: https://www.reportspedia.com/report/life-sciences/global-molecular-diagnostic-product-market-report-2019,-competitive-landscape,-trends-and-opportunities/29662 #request_sample

Key Players:

SiemensBiotestIlluminaBioMerieuxAbbottTecan GroupFujirebioGrifolsCepheidKreatech/LeicaAffymetrixBiokitLi-Cor BiosciencesSierra MolecularOrtho-Clinical DiagnosticsElitech GroupApplied Gene TechnologiesMyriad GeneticsRocheTakara BioDiadexusBio-RadEnzoProteome SciencesShimadzuPerkin Elmer/CaliperAgilent TechnologiesMonogram Biosciences/LabCorpSequenomDecode GeneticsExact SciencesEikenScienionQiagenBecton DickinsonHologic/Gen-ProbeCellMark Forensics/LabCorpThermo FisherArca BiopharmaBeckman Coulter/Danaher

The Molecular Diagnostic Product industry report offers in-depth analysis and insights into developments impacting businesses and enterprises on a global & regional level. A detailed breakdown of key trends, drivers, restraints, and opportunities influencing revenue growth is presented in this research report. This study focuses on the global Molecular Diagnostic Product market by share, volume, value, and regional appearance along with the types and applications. The market is divided into the below points:

Market by Type/Products:

Type 1Type 2Type 3

Market by Application/End-Use:

Application 1Application 2Application 3

Enquire or share your questions if any before the purchasing this report @ https://www.reportspedia.com/report/life-sciences/global-molecular-diagnostic-product-market-report-2019,-competitive-landscape,-trends-and-opportunities/29662 #inquiry_before_buying

The geographical analysis covers the following regions:

The Molecular Diagnostic Product market research answers important questions, including the following:

The Molecular Diagnostic Product market research serves a platter of the following information:

In-depth analysis of the drivers, restraints, opportunities and trends influencing the growth of the global Molecular Diagnostic Product market. Critical breakdown of the Molecular Diagnostic Product market as per product type, and end use industry. Exhaustive understanding of the strengths, weaknesses, opportunities and threats of various Molecular Diagnostic Product market players. Precise year-on-year growth of the global Molecular Diagnostic Product market in terms of value and volume.

Key questions answered by this report include:

Table of contents:

Click here to access Detailed Table of Contents @ https://www.reportspedia.com/report/life-sciences/global-molecular-diagnostic-product-market-report-2019,-competitive-landscape,-trends-and-opportunities/29662 #table_of_contents

Thanks A Million For Reading This Article!!!

More here:
Global Molecular Diagnostic Product Market Analysis And Forecast To 2026 By Recent Trends, Developments In Manufacturing Technology And Regional...

Read More...

University researchers show how a protein found – Mirage News

Tuesday, February 25th, 2020

Researchers at the University of Toronto have found that a receptor expression-enhancing protein contributes to normal heart development and function by regulating the sarcoplasmic reticulum, a network of tubules found in cardiac muscle cells.

The sarcoplasmic reticulum is key in the development and progression of heart disease, governing biochemical changes, structural remodeling and deterioration. But how this membrane-bound system organizes itself is still mostly unknown especially in cells with a highly differentiated or diverse network such as heart muscle cells, or cardiomyocytes.

Our findings show that a protein called REEP5 plays a critical role in regulating cellular stress responses in heart muscle cells, says Frank Shin-Haw Lee, a PhD student in the lab of Anthony Gramolini, an associate professor of physiology in U of Ts Faculty of Medicine who is based at the Ted Rogers Centre for Heart Research.

When REEP5 is depleted, it destabilizes the heart and reduces the amount of blood the heart can pump on each contraction, says Lee. When we removed this protein in both mice and zebrafish, it distorted the structure and shape of cardiomyocytes and led to cardiac dysfunction.

The journal Nature Communications published the findings this week.

When cardiomyocytes are under sustained stress from general dysfunction or disease, cellular pathways through the sarcoplasmic reticulum can lead to cell death and heart failure. Lee says that REEP5 is vital to the formation of the sarcoplasmic reticulum and to how it responds to stress and regulates calcium, which is essential for heart health.

A better understanding of how REEP5 functions in the heart may elucidate how heart failure develops amidst a sarcoplasmic reticulum in stress, Lee says.

The Gramolini lab worked with several other Toronto researchers on the study, including Ian Scott, a professor of molecular genetics at U of T and a senior scientist at the Hospital for Sick Children. The work builds on previous collaborative research from the labs of Gramolini, Scott and medical biophysics professor Thomas Kislinger in 2015, which created a blueprint of critical cell-surface and membrane-associated proteins in the heart.

Medical student Sina Hadipour-Lakmehsari was a co-first author on the current paper with Lee, and he says the findings may provide insight into heart disease in patients.

It is clearly an important protein for cardiac development and function and, combined with future human studies, it may help us unearth new potential therapies, Hadipour-Lakmehsari says, adding that the lab can continue to look at REEP5 in genetic studies to help shed light on diseases whose causes remain unknown.

This study is among the first in the world to show that the REEP5 protein plays an essential role in the stress responses that often lead to heart failure, adds Gramolini, who is also a scientist at Toronto General Hospital Research Institute, University Health Network. Deciphering the complex layers of heart function on a cellular level will help us generate new therapeutic and preventative strategies for heart failure.

The study recieved support from the Ted Rogers Centre Innovation Fund, the Natural Sciences and Engineering Research Council of Canada and the Canadian Institutes of Health Research, among others.

Continued here:
University researchers show how a protein found - Mirage News

Read More...

Radiation Kills Cancer Cells, But May Also Protect Some Tumor Stem Cells That Can Spread – MedicalResearch.com

Tuesday, February 25th, 2020

MedicalResearch.com Interview with:

Jennifer Sims-Mourtada, Ph.D.Senior Rsearch ScientistDirector of Translational Breast Cancer ResearchCenter for Translational Cancer ResearchChristianaCare

MedicalResearch.com: What is the background for this study?

Response: Cancer stem cells are resistant cancer cells that are able to continuously grow and are very resistant to radiation and chemotherapy. Cancer stem cells can also escape to the blood stream and travel to another site causing metastasis.

MedicalResearch.com: What are the main findings?

Response: In this study we show that cancer stem cells depend on radiation induced inflammatory responses to survive radiation. Additionally we show that activation of IL-6-STAT3 pathway after radiation can make even non-cancer stem cells look like and behave as cancer stem cells. Thus any cell that survives radiation in the presence of certain inflammatory signals may be converted to a cancer stem cell.

MedicalResearch.com: What should readers take away from your report?

Response: Although radiation kills tumor cells, it can also activate inflammatory responses that may protect some tumor cells. Co-treatment with anti-inflammatory agents such as inhibitors to the IL-6 STAT 3 pathway may sensitize cancer stem cells to radiation induced death, and may prevent generation of new cancer stem cancer stem cells and improve outcomes in triple negative breast cancer.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: Agents inhibiting the IL-6-STAT3 pathway are currently in clinical trials for breast cancer. Future work should focus on understanding radiation-induced inflammation in the context of both the immune response and tumor cells, as radiation induced inflammation can activate anti-tumor immunity as well as killing tumor cells. Some studies suggest that inhibition of IL-6 STAT3 signaling may also improve anti-tumor immunity, and thus these agents may target cancer cells by multiple mechanisms. It will be important to understand how these agents work to select which patients will respond to inhibition of this pathway and which ones will not.

MedicalResearch.com: Is there anything else you would like to add?

Response: This is the good and the bad of radiation. We know radiation induced inflammation can help the immune system to kill tumor cells thats good but also it can protect cancer stem cells in some cases, and thats bad. Whats exciting about these findings is were learning more and more that the environment the tumor is in its microenvironment is very important. Historically, research has focused on the genetic defects in the tumor cells. Were now also looking at the larger microenvironment and its contribution to cancer.

There are no disclosures to report

Citation:

Kimberly M. Arnold et al, Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells,International Journal of Radiation Biology(2019).DOI: 10.1080/09553002.2020.1705423

We respect your privacy and will never share your details.

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

More here:
Radiation Kills Cancer Cells, But May Also Protect Some Tumor Stem Cells That Can Spread - MedicalResearch.com

Read More...

Why Some COVID-19 Cases Are Worse than Others – The Scientist

Tuesday, February 25th, 2020

Like many other respiratory conditions, COVID-19the disease caused by SARS-CoV-2can vary widely among patients. The vast majority of confirmed cases are considered mild, involving mostly cold-like symptoms to mild pneumonia, according to the latest and largest set of data on the new coronavirus outbreak released February 17 by the Chinese Center for Disease Control and Prevention.

Fourteen percent of confirmed cases have been severe, involving serious pneumonia and shortness of breath. Another 5 percent of patients confirmed to have the disease developed respiratory failure, septic shock, and/or multi-organ failurewhat the agency calls critical cases potentially resulting in death. Roughly 2.3 percent of confirmed cases did result in death.

Scientists are working to understand why some people suffer more from the virus than others. It is also unclear why the new coronaviruslike its cousins SARS and MERSappears to be more deadly than other coronaviruses that regularly circulate among people each winter and typically cause cold symptoms. I think its going to take a really, really long time to understand the mechanistic, biological basis of why some people get sicker than others, says Angela Rasmussen, a virologist at Columbia Universitys Mailman School of Public Health.

In the meantime, the latest data from China and research on other coronaviruses provide some hints.

The latest data from China stem from an analysis of nearly 45,000 confirmed cases, and on the whole suggest that the people most likely to develop severe forms of COVID-19 are those with pre-existing illnesses and the elderly.

While less than 1 percent of people who were otherwise healthy died from the disease, the fatality rate for people with cardiovascular disease was 10.5 percent. That figure was 7.3 percent for diabetes patients and around 6 percent for those with chronic respiratory disease, hypertension, or cancer.

While overall, 2.3 percent of known cases proved fatalwhich many experts say is likely an overestimate of the mortality rate, given that many mild cases might go undiagnosedpatients 80 years or older were most at risk, with 14.8 percent of them dying. Deaths occurred in every age group except in children under the age of nine, and, generally speaking, we see relatively few cases among children, World Health Organization Director General Tedros Adhanom Ghebreyesus said last week.

This pattern of increasing severity with age differs from that of some other viral outbreaks, notably the 1918 flu pandemic, for which mortality was high in young children and in people between 20 and 40 years of age. However, its broadly consistent with records of the SARS and MERS coronavirus outbreaks, notes Lisa Gralinski, a virologist at the University of North Carolina at Chapel Hill. If youre over fifty or sixty and you have some other health issues and if youre unlucky enough to be exposed to this virus, it could be very bad, she says.

I think its going to take a really, really long time to understand the mechanistic, biological basis of why some people get sicker than others.

Angela Rasmussen, Columbia University

Scientists dont know what exactly happens in older age groups. But based on research on other respiratory viruses, experts theorize that whether a coronavirus infection takes a turn for the worse depends on a persons immune response. The virus matters, but the host response matters at least as much, and probably more, says Stanley Perlman, a virologist and pediatric infectious disease specialist at the University of Iowa.

Once SARS-CoV-2 gets inside the human respiratory tract, its thought to infect and multiply in cells lining the airway, causing damage that kicks the immune system into action. In most people, it should trigger a wave of local inflammation, recruiting immune cells in the vicinity to eradicate the pathogen. The immune response then recedes, and patients recover.

For reasons that arent entirely clear, some peopleespecially the elderly and sickmay have dysfunctional immune systems that fail to keep the response to particular pathogens in check. This could cause an uncontrolled immune response, triggering an overproduction of immune cells and their signaling molecules and leading to a cytokine storm often associated with a flood of immune cells into the lung. Thats when you end up with a lot of these really severe inflammatory disease conditions like pneumonia, shortness of breath, inflammation of the airway, and so forth, says Rasmussen.

Local inflammation can turn into widespread inflammation of the lungs, which then has ripple effects across all organs of the body. This could also happen if the virus replicates faster than the immune system can respond, so that it then has to play catch-up to contain the pathogena situation that could also cause the immune defense to spiral out of control. With mice, we know that in some cases, particularly for SARS and MERS coronaviruses, virus replication is very rapid and in some cases overwhelming to the immune system, says Perlman.

Its harder to explain why young, healthy people also sometimes die from the diseasefor instance, Li Wenliang, a 34-year-old doctor who first sounded the alarm about the virus. He died a few weeks after contracting the pathogen.

Genetic and environmental risk factors might help explain the severity of infections. Though its clear that genetic factors can strongly determine the outcome of viral infections in miceas some of Rasmussens work has shown for Ebola, for instanceresearchers havent yet been able to tease out specific genes or variants in mice, let alone in people, that are responsible for varying degrees of illness. Environmental factors, such as smoking or air quality, may also play a role in disease severity, Rasmussen adds.

A lot of research has gone into understanding what causes respiratory failure that results from systemic inflammation of the lungsalso called acute respiratory distress syndrome (ARDS)that can occur from coronaviruses and other infections. Yet researchers still dont know how it occurs exactly, let alone how to treat it, Gralinksi notes. Its still a really poorly understood issue.

An intriguing finding in the new data released last week is that although similar numbers of men and women have contracted SARS-CoV-2, more men are dying from the disease. The death rate for males was 2.8 percent and 1.7 percent for women. Rasmussen is quick to caution that although the data encompass nearly 45,000 patients, thats still not that many people to determine if theres really a gender biasyoud have to look at this in a much larger population of patients in a number of different countries, she says.

That said, if there is a bias, it would be consistent with what epidemiologists have observed during the SARS and MERS outbreaks. In the 2003 SARS outbreak in Hong Kong, for instance, nearly 22 percent of infected men died, compared to around 13 percent of women. In an analysis of MERS infections between 2017 and 2018, around 32 percent of men died, and nearly 26 percent of women. The difference could have something to do with the fact that the gene for the ACE-2 receptor, which is used by both SARS-CoV-2 and the SARS virus to enter host cells, is found on the X chromosome, she speculates. If its a particular variant of the protein that makes people more susceptible to the virus, then females could compensate for that one bad variant because theyd have two copies of the X chromosome, whereas men would be stuck with only one copy. Or, it could be that men are more likely to be smokers and so their lungs are already a bit compromised. Theres definitely more to be teased out there, Gralinski says.

Some of Perlmans research, which demonstrated that the sex disparity also holds true in SARS-infected mice, points to the hormone estrogen as possibly having protective effects: Removing the ovaries of infected female mice or blocking the estrogen receptor made the animals more likely to die compared to infected control mice. The effects are probably more pronounced in mice than in people, Perlman tells The New York Times.

Whether patients develop antibodies after SARS-CoV-2 infection that will protect them against future infections is still a mystery. Surveys of SARS patients around five or 10 years after their recovery suggest that the coronavirus antibodies dont persist for very long, Gralinski says. They found either very low levels or no antibodies that were able to recognize SARS proteins.

However, for the new coronavirus, we would expect some immunity, at least in the short term, she says.

There are seven coronaviruses known to infect people. Four of them229E, NL63, OC43, and HKU1typically cause a cold and only rarely result in death. The other threeMERS-CoV, SARS-CoV, and the new SARS-CoV-2have varying degrees of lethality. In the 2003 SARS outbreak, 10 percent of infected people died. Between 2012 and 2019, MERS killed 23 percent of infected people. Although the case fatality rate of COVID-19 is lower, the virus has already killed more people than the other two outbreaks combined, which some have attributed to the pathogens fast transmission.

The cold-causing coronaviruses, as well as many other viruses that cause common colds, are typically restricted to the upper respiratory tract, that is, the nose and sinuses. Both SARS-CoV and SARS-CoV-2, however, are capable of invading deep into the lungs, something that is associated with more severe disease.

One possible reason for this is that the virus binds to the ACE-2 receptor on human cells in order to gain entry. This receptor is present in ciliated epithelial cells in the upper and lower airway, as well as in type II pneumocytes, which reside in the alveoli in the lower airway and produce lung-lubricating proteins. The type II pneumocytes are . . . important for lung function, so this is part of why the lower respiratory disease can be so severe, notes Gralinksi.

The new coronavirus also appears to use the ACE-2 receptor, which may help partially explain why, like SARS, it is more deadly than the other four coronaviruses. Those pathogens use different receptors, except for NL63, which also uses the ACE-2 receptor but binds to it with less affinity, says Gralinski. (MERS is thought to use an entirely different receptor, which is also present in the lower airways.)

To understand these questions fully will take time, research, and consistent funding for long-term studies. Coronavirus funding has been criticized for following a boom-and-bust cycle; viral spillovers from animals to people cause an initial surge of interest that tends to wane until the next outbreak occurs, Rasmussen warns.

Im hopeful that in this case it will be really apparent to everybody in the world that we need to be funding this type of basic science, fundamental science, to understand these mechanisms of disease, she says. Otherwise, were going to be in the same situation when the next outbreak happenswhether its a coronavirus or something else.

Katarina Zimmer is a New Yorkbased freelance journalist. Find her on Twitter@katarinazimmer.

The rest is here:
Why Some COVID-19 Cases Are Worse than Others - The Scientist

Read More...

Precision Medicine Software Market Growing Rapidly with Significant CAGR of +10% by 2026 Syapse, Allscripts, Qiagen, Roper Technologies, Fabric…

Tuesday, February 25th, 2020

Precision Medicine Software Market research report has been published by A2Z Market Research to give desired insights to drive the growth of businesses. The report initiated with study introduction which is followed by statistical details of the market that reveals the current market status and future forecast. The analysts have scrutinized the market drivers, confinements, risks, and openings present in the overall market.

The Global Precision Medicine Software market size was increased to xx million US$ from xx million US$ in 2015, and it will reach xx million US$ in 2026, growing at CAGR of +10 % between 2020 and 2026.

Precision medicine software enables stakeholders in the healthcare sector to provide personalized treatment plans to patients based on their genetic content. It combines clinical and genetic data to deliver targeted patient care. It also provides a wide range of applications in both the diagnostic and clinical areas of care delivery.

Get Sample copy of this Report @: https://www.a2zmarketresearch.com/sample?reportId=79150

Some of the Top Companies Profiled in this Report includes: Syapse, Allscripts, Qiagen, Roper Technologies, Fabric Genomics, Foundation Medicine, Sophia Genetics, PierianDx, Human Longevity, Translational Software, Gene42, Lifeomic Health.

This report provides a detailed and analytical look at the various companies that are working to achieve a high market share in the global Precision Medicine Software market. Data is provided for the top and fastest growing segments. This report implements a balanced mix of primary and secondary research methodologies for analysis. Markets are categorized according to key criteria. To this end, the report includes a section dedicated to the company profile. This report will help you identify your needs, discover problem areas, discover better opportunities, and help all your organizations primary leadership processes. You can ensure the performance of your public relations efforts and monitor customer objections to stay one step ahead and limit losses.

Global Precision Medicine Software Market Detail Segmentation:

Market Segment by Type:

Market Segment by Applications:

Get Special Discount on this Report @: https://www.a2zmarketresearch.com/discount?reportId=79150

The main points which are answered and covered in this Report:

Table of Contents

Global Precision Medicine Software Market Research Report 2020 2026

Chapter 1 Precision Medicine Software Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Precision Medicine Software Market Forecast

Buy Complete Report @: https://www.a2zmarketresearch.com/buy?reportId=79150

If you have any special requirements, please let us know and we will offer you the report as you want.

See more here:
Precision Medicine Software Market Growing Rapidly with Significant CAGR of +10% by 2026 Syapse, Allscripts, Qiagen, Roper Technologies, Fabric...

Read More...

E.coli bacteria running the Internet of Things – IOL

Tuesday, February 25th, 2020

Technology/23 February 2020, 3:48pm/Louis Fourie

CAPE TOWN One of the areas of the Fourth Industrial Revolution (4IR) that has seen phenomenal growth over the past few years is that of bioscience and bioengineering. But when bioscience is combined with computer science, it seems that we may one day have biological computing devices that could partly replace the current hard drives, silicon microprocessors and microchips.

At least this is what some scientists firmly belief is possible.

Through the study of genetics we know that all living organisms consists of genes and deoxyribonucleic acid or DNA. These strings of DNA contains huge amounts of data that can last thousands of years as is evident from the 45 000 year old human femur bone from Siberia that was DNA-sequenced or decoded a few years ago.

It is exactly this remarkable data density and longevity of DNA that got scientists interested. Scientists have therefore been researching a synthetic form of DNA sequencing to store large quantities of data for an indefinite period of time. Recently scientists from Microsoft and the University of Washington announced that they were making very good progress. Already in 2018 they were already able to store 200 MB of data in DNA format and were able to retrieve it with zero errors.

Since 2018 much progress has been made and it seems very likely that DNA storage could complement current data storage methods or even replace some of them in the future. Perhaps Microsoft Researchs target of a DNA storage system functioning within a data centre by the turn of the decade is not so far-fetched.

Due to advances in nano- and biotechnology scientists at the Queen Mary University in London are taking research further and are using microbes to network and communicate at nanoscale, which is of particular interest to the Internet of Things (IoT).

In a 2019 paper by Raphael Kim and Stefan Poslad titled The thing with E.coli: Highlighting Opportunities and Challenges of Integrating Bacteria in IoT and HCI the researchers explain that it is not only the minute size, but also the autonomous nature of bacteria that caught their attention and presents interesting possibilities. Bacteria have an embedded, natural propeller motor or whip-like structure, called flagella, that propels them forward.

The research is still at an early stage but the exploitation of similarities between bacteria and computing devices is of great interest to the future of computing. The microbes share interesting similarities with some components of typical IoT devices, which indicate that bacteria could be used as a living form of an IoT device.

A good example would be the field of environmental IoT where bacteria could be programmed and deployed in the sea or in smart cities to detect toxins or pollutants, gather data, and even undertake the biomediation processes.

Likewise, in healthcare and medicine, bacteria could be programmed and deployed to treat specific diseases. The bacteria could swim to a pre-determined destination in the human body, then produce and release encoded hormones when triggered by the microbes internal sensor.

Microbes have exceptional chemical sensing, as well as actuating, communication and processing capabilities typical of a computerised IoT and could even outperform the best electronic devices. Bacteria cannot only detect chemicals, but also electromagnetic fields, light, mechanical stress, and temperature, as is normally done by traditional electronic sensors. The bacteria can also respond to these stimuli through movement using their flagella, or through the production of coloured proteins.

In fact bacteria are better than electronic chip-based sensors, since they are much more sensitive, stable and responsive than their digital counterparts. This superior qualities makes bacteria especially useful as a living form of IoT device and also valuable in the field of Human Computer Interaction (HCI).

Just like a digital control unit, memory and processor, the programmed DNA controls the bacteria and functions as a control unit with regard to the collection (sensing), processing and storing of data. Genomic DNA contains the instructions for the functioning of the bacteria, while the smaller circular plasmids (a form of DNA used to introduce genes into organisms) determine the process functions through gene addition and subtraction, as well as the storage of new data.

According to the team from the Queen Mary University the cellular membrane functions as the transceiver and allows for both the transmission and reception of communication. This molecular communication or the DNA exchange between cells forms the basis of a bacterial nanonetwork or signalling pathway.

This possibility of bacterial networks as an example of molecular communication such as the widely known E.coli bacterium that could act as an information carrier has in particular excited the IoT community.

The research with digital-to-DNA data and back again from DNA-to-digital data is showing great promise for the future. The idea of the researchers is to use the bacteria to create a potential substrate for the Internet of Bio-Nano Things (IoBNT), which entails the networking and communication through nanoscale and biological entities. Some of the often-despised bacteria may indeed change our connected world of sensors and IoT devices in the future.

Interesting is that the researchers from the Queen Mary University, London closes their research paper with a passionate plea for experimentation with do-it-yourself technology by enthusiasts to promote the IoBNT. They refer to the easily obtainable and affordable educational products like the Amino Labs Kit that are widely available to the public and allow, for example, many bioengineering experiments such as the generation of specific colours from bacteria through the programming of K12 E.coli DNA. Tools, data, and materials of biotechnology that enable the broader public to run small-scale experiments with microorganisms are currently easily accessible and affordable.

The Amino Labs Kit, for instance, caters for people who are interesting in manipulating and genetically engineering E.coli bacteria. The kit enables the user to create customised living colours and smells through the building of genetic circuits that can be triggered through a variety of pre-determined environmental stimuli.

This call by the researchers is not so unusual since technology hobbyists that experimented with very affordable Arduino microcontrollers and Rasberry Pi mini-computers were the very people that significantly advanced the traditional IoT. The mini-computers and the building of sensors and IoT controller devices were the learning space of many very successful technologists and scientists.

Due to the hard work of bioscientists around the world, programming of DNA is improving our quality of life in many instances and is keeping diseases at bay. It is therefore logical that the number of genetically engineered products will continue to rise in the future since it is one of of the 4IR.

Biotechnology en bioengineering will play an increasingly important role as major building blocks of the 4IR. Do-it-yourself and educational bio-kits can therefore teach potential future scientists how to effectively program bacteria. And perhaps some of the young bioengineers, learning the skills and concepts of the future, may one day become the scientists that solve the challenges of cancer, hunger, waste and climate change.

Todays adventures in science create tomorrows innovators. And it all starts with a string of DNA and an unpretentious bacterium.

Professor Louis C H Fourie is a futurist and technology strategist.[emailprotected]

BUSINESS REPORT

See the article here:
E.coli bacteria running the Internet of Things - IOL

Read More...

This Dior Serum Is Basically The Fountain Of Youth | BEAUTY/crew – BEAUTYcrew

Tuesday, February 25th, 2020

The serum can reach deeper into the skin

Besides the star-studded line-up of ingredients, the formula features a clever delivery system that helps it go deeper into your skin. In particular, the formula features a bio-fermented lipopeptide (which is a probiotic to regulate the pH of your skin) which, when combined with the floral and hyaluronic acid ingredients, can improve the rate of penetration by 30 per cent. So, what does this mean? Well, it allows for quicker absorption, making it perfect to use both morning before applying foundation, and at night before going to bed.

The beauty of Dior Capture Totale Super Potent Serum is that it doesnt just do one thing - it actually addresses all aspects of ageing, as proven by 600 women from France, China and Japan*. The panel revealed that after continuous use, their skin looked brighter and smoother, and felt bouncier and stronger. And who doesnt want a complexion that looks and feels seriously healthy?

Like all good skin care products, the Super Potent Serum does its best work when its supported by a great team. There are four other products in the Capture Totale range that are also formulated with natural-origin ingredients. When used as a complete skin care routine the range delivers even more impressive anti-ageing results.

Dior Capture Totale High-Performance Gentle Cleanser: This cleanser can effectively remove dirt and sebum without aggravating skin and can improve skins softness.

Dior Capture Totale High-Performance Serum-Lotion: Pop a few drops of this hydrating product onto a cotton pad or the palms of your hands and press it all over your face for juicy-looking skin. Vitamins C, E and B3 in the formula have brightening and soothing qualities.

Dior Capture Totale Firming & Wrinkle-Correcting Crme: Dont underestimate its lightweight texture; this moisturiser can dial up radiance, fill fine lines and smooth skin in the long run. A special shout-out goes to the bio-fermented ceramides that help improve the skins barrier.

Dior Capture Totale Firming & Wrinkle-Correcting Eye Cream: Want to brighten and strengthen the skin around your eyes? Look no further than this phytosterols-enriched eye cream that works to firm up the delicate area.

See the rest here:
This Dior Serum Is Basically The Fountain Of Youth | BEAUTY/crew - BEAUTYcrew

Read More...

Global Precision Medicine Software Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Market Trends Adopted by the…

Tuesday, February 25th, 2020

Precision Medicine Software market Research Report 2020 offers a comprehensive analysis of the market growth drivers, trends, opportunities, prospects, drivers and restrictions inside the market. The report emphasizes to meet the requirement of customers by providing complete knowledge of the Precision Medicine Software Industry. This carefully organised report is formulated by industry experts and professional experts, in terms of demand and supply, cost organization, barriers and challenges, product category, crucial market players, technology, regions, and applications.

The Precision Medicine Software market study is based on historical information and present market requirements. As well as includes different business approaches preferred by the decision-makers. That enhanced the Precision Medicine Software industry growth and make a phenomenal stand in the industry. The market will raise with a prominentCAGRby 2020 to 2026.

Download Free Sample Report

https://www.reportspedia.com/report/technology-and-media/global-precision-medicine-software-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/32812 #request_sample

Furthermore, it also evaluates the most recent improvements while estimating the growth of theleading playerslike

SyapseAllscriptsQiagenRoper TechnologiesFabric GenomicsFoundation MedicineSophia GeneticsPierianDxHuman LongevityTranslational SoftwareGene42, IncLifeomic Health

Segmentation by Product Type

Cloud-basedOn-premise

Segmentation by Application/ End uses:

Healthcare ProvidersPharmaceutical and Biotechnology CompaniesResearch Centers and Government InstitutesOthers

Regional Analysis for Precision Medicine Software Market:

North America (the United States, Canada & Rest of the countries)

Europe (Germany, The UK, France, Netherlands, Italy, Spain & the rest of the countries)

Asia-Pacific (China, Japan, Korea, India, & rest of the countries)

Middle East & Africa (South Africa, Israel, UAE & rest of the countries)

South America (Brazil, Colombia, Argentina & the rest of the countries)

Ask For discount

https://www.reportspedia.com/discount_inquiry/discount/32812

What is the regional structure of the market? Our analysis-

The Precision Medicine Software Industry report analyses footprint of every product and its significance analyzes examine each geographical segment of the market with import, export, consumption, and production in these regions to provide a complete understanding of the Precision Medicine Software market

In addition, the Precision Medicine Software Industry report covers an analysis of different products available in the global market built on production, volume, revenue, and cost and price structure. The Precision Medicine Software Market report also highlights key strategies that proved to be profitable for the business in-line with the policies involved in business expansion, partnership deals, composition, and new product/service launches.

YEARS CONSIDERED FOR THIS REPORT:

Historical Years:2015-2019

Base Year:2019

Estimated Year:2020

Forecast Period:2020-2026

DEFINITE SEGMENTS OF GLOBAL Precision Medicine Software INDUSTRY:

The analysis highlights a region-wise as well as a worldwide study of the Precision Medicine Software market. Proportionately, the regional study of the industry comprisesJapan, South East Asia, India, the USA, Europe, and China.Moreover, the report reviews an in-depth market analysis of distinct manufacturers and suppliers. It explainsindustry chain structure, competitive scenario, and study of Precision Medicine Software industry costin detail. It evenly analyzes global industry size pursued by forecast period (2020-2026) and environment.

Ask For Report Customization

https://www.reportspedia.com/inquiry/customization/32812

The analysis covers basic information about the Precision Medicine Software product likeindustry scope, segmentation, anoverviewof the market. Likewise, it providessupply-demand data, investment feasibleness, and elements that limiting the growth of an industry. Predominantly, it helps product demand, annual revenue and growth prospects of the industry. The foreseen Precision Medicine Software market regions along with the present onesassist leading vendors, decision-makers, and viewers/readersto plan effective business strategies respectively.

KEY TOPIC COVERED

Growth Opportunities

Market Growth Drivers

Leading Market Players

Market Size and Growth Rate

Market Trend and Technological

Company Market Share

TOC OF Precision Medicine Software MARKET REPORT INCLUDES:

1 Industry Overview of Precision Medicine Software

2 Industry Chain Analysis

3 Manufacturing Technology

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Precision Medicine Software by Regions, Creators, Types, and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate by 2013-2019

7 Consumption Volumes, Consumption Value, Import, Export and Sale Price Analysis by Regions

8 Gross and Gross Margin Analysis

9 Marketing Traders or Distributor Analysis

10 Global and Chinese Economic Impacts on the Precision Medicine Software Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Precision Medicine Software Industry 2019 Market Research Report Continued

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Key questions answered by the Precision Medicine Software Report:

What are some of the most favourable, high-growth prospects for the global Precision Medicine Software market?

Which products segments will raise at a faster pace throughout the forecast period and why?

What are the foremost factors impacting market prospects?

What are the driving factors, restraints, and challenges in this Precision Medicine Software market?

What are the competitive threats and challenges to themarket?

What are the evolving trends in this Precision Medicine Software market and reasons behind their emergence?

What are some of the changing customer demands in the Precision Medicine Software Industry market?

Continue

Explore More Information

https://www.reportspedia.com/report/technology-and-media/global-precision-medicine-software-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/32812 #table_of_contents

View post:
Global Precision Medicine Software Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Market Trends Adopted by the...

Read More...

Genetic engineering company says they have created a coronavirus vaccine – 9News.com KUSA

Tuesday, February 25th, 2020

HOUSTON A Houston-based genetic engineering company said it has a vaccine aimed at the deadly coronavirus outbreak, according to a report by the Houston Business Journal.

The genetic engineering firm, Greffex Inc. has one of its laboratories based in Aurora, Colorado.

RELATED: Coronavirus death toll hits 2,100 in mainland China

RELATED: Colorado man living in China posts brutally honest Instagram videos of coronavirus self-quarantine

John Price, president and CEO of Greffex Inc., told KHOU, our sister station in Houston, that Greffex's scientists completed the coronavirus vaccine this week.

The trick in making a vaccine is can you scale the vaccine that youve made to be able to make a certain number of doses, can you test the vaccine quickly and efficiently and then can you get it into patients and thats where we have an edge as well on the other companies that are out there," said Price. "And that has to do with speed and essential uniformity of how we make vaccines, so that drops the cost down.

Price said the vaccine will now move into a testing phase with the Food and Drug Administration.

The Houston Business Journal reported, in September 2019 Greffex received an $18.9 million contract from the National Institute of Health's National Institute for Allergy and Infectious Diseases to develop new treatments for infectious threats.

If the vaccine gets government approval, Price said his company plans to give it away for free to nations hit hard by the coronavirus outbreak.

SUGGESTED VIDEOS | Local stories from 9NEWS

More here:
Genetic engineering company says they have created a coronavirus vaccine - 9News.com KUSA

Read More...

Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 – ResearchAndMarkets.com – Yahoo Finance

Tuesday, February 25th, 2020

The "Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.

The global gene therapy market was valued at $393.35 million in 2018, and is estimated to reach $6,205.85 million by 2026, registering a CAGR of 34.8% from 2019 to 2026.

Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient's cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. On the contrary, increase in the pipeline developments for gene therapy market are expected to provide lucrative opportunity during the forecast period.

Key MARKET BENEFITS FOR STAKEHOLDERS

Key Findings of the Gene Therapy Market:

Key Topics Covered:

Chapter 1: Introduction

1.1. Report Description

1.2. Key Benefits

1.3. Key Market Segments

1.4. Research Methodology

Chapter 2: Executive Summary

2.1. CXO Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope

3.2. Key Findings

3.3. Top Player Positioning, 2018

3.4. Porter's Five Forces Analysis

3.5. Market Dynamics

Chapter 4: Gene Therapy Market, By Vector Type

4.1. Overview

4.2. Viral Vectors

4.3. Non-Viral Techniques

Chapter 5: Gene Therapy Market, By Gene Type

5.1. Overview

5.2. Antigen

5.3. Cytokine

5.4. Tumor Suppressor

5.5. Suicide Gene

5.6. Deficiency

5.7. Growth Factors

5.8. Receptors

5.9. Others

Chapter 6: Gene Therapy Market, By Application

6.1. Overview

6.2. Oncological Disorders

6.3. Rare Diseases

6.4. Cardiovascular Diseases

6.5. Neurological Disorders

6.6. Infectious Diseases

6.7. Other Diseases

Chapter 7: Gene Therapy Market, By Region

7.1. Overview

7.2. North America

7.3. Europe

7.4. Asia-Pacific

7.5. LAMEA

Chapter 8: Company Profile

8.1. Adaptimmune Therapeutics Plc.

8.2. Anchiano Therapeutics Ltd.

8.3. Achieve Life Sciences, Inc.

8.4. Adverum Biotechnologies, Inc.

8.5. Abeona Therapeutics Inc.

8.6. Applied Genetic Technologies Corporation

8.7. Arbutus Biopharma Corporation

8.8. Audentes Therapeutics Inc.

8.9. Avexis Inc.

8.10. Bluebird Bio, Inc.

8.11. Celgene Corporation

8.12. Crispr Therapeutics Ag

8.13. Editas Medicine, Inc.

8.14. Gilead Sciences, Inc.

8.15. Glaxosmithkline Plc

8.16. Intellia Therapeutics Inc.

8.17. Merck & Co., Inc.

8.18. Novartis Ag

8.19. Regenxbio, Inc.

8.20. Spark Therapeutics, Inc.

8.21. Sangamo Therapeutics, Inc.

8.22. Uniqure N. V.

8.23. Voyager Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/yt2y68

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005742/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T. Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the original here:
Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 - ResearchAndMarkets.com - Yahoo Finance

Read More...

Pet food makers look to tap the alternative meat market – Marketplace

Tuesday, February 25th, 2020

New pet food companies are springing up to meet what they say is growing demand for plant-based, sustainable alternatives to Fancy Feast and Kibbles N Bits.

By making products from fermented fungus and experimenting with lab-grown food from animal cells and microbes, alternative pet food makers are hoping to carve out a share of the $30 billion U.S. pet food market.

And multibillion-dollar pet food companies, like Mars Petcare and Nestl-owned Purina, are starting to take notice.

Our mission is almost the exact same as Impossible Foods, which is [to] reduce or eliminate factory farming, which has this giant environmental footprint, said Josh Errett, CFO of Because Animals, one of the companies developing new pet foods. I mean, calling it a footprint is too nice, its an environmental disaster.

The other mission is to make a profit. These companies are catering to pet owners who value their ecological footprint and have the income to pay for an alternative product that tends to be more expensive than a can of Pedigree.

Pulling away from factory farming

A UCLA study from 2017 by Professor Gregory Okin estimated that dog and cat food accounts for the release of millions of tons of the greenhouse gases methane and CO2 and constitutes about 25%30% of the environmental impacts from animal production in terms of the use of land, water, fossil fuel, phosphate and biocides.

Like plant-based market leaders Impossible Foods and Beyond Meat, alternative pet food companies say their product will reduce the amount of land and energy used for conventional meat production.

Industrial animal farming, or concentrated animal feed operations, produce large amounts of byproducts and off-cuts like organs and bone meal which are not usually used in human food, but are re-purposed for pet food production.

The goal is to cut factory farming out of the supply chain completely without a market for the unused parts, the meat industry would collapse due to lost revenue, Errett said.

But many large pet food companies defend their use of animal byproducts.

One might argue that this is actually a super sustainable source, because were using materials that most of us wouldnt consume and would be wasted, said Richard Butterwick, global nutrition advisor at the Waltham Petcare Science Institute, a research center for Mars Petcare.

Because Animals along with another company, Wild Earth are using cellular technology to culture real meat from animal cells biopsied from living creatures. The cells are encouraged to proliferate and reproduce in a bioreactor, creating muscle protein without the need to slaughter animals. This process is also being used by more than 30 companies worldwide to develop clean or lab-grown meat for human consumption.

Next year, both Because Animals and Wild Earth hope to release their first cell-grown cat foods, made of cultured mouse meat.

Were getting back to what the cats system was built to digest, Errett said. You dont have to add taurine or anything back, you can make an ancestral diet.

A cat owner himself, Errett wanted to address the ultra-processed nature of a lot of the conventional cat food, or as he calls it biological waste. Cats are obligate carnivores, meaning they need to eat meat to get the 11 essential amino acids they require or they could have serious health problems like blindness or even death.

By culturing animal meat in a lab, these companies can genetically control what nutrients present in the food. They can also eliminate potentially dangerous substances that have made their way into some conventional pet foods. Some popular pet foods companies have had to recall their products in recent years due to toxic levels of Vitamin D and even the euthanasia drug sodium pentobarbital.

Will pet owners buy lab-grown mouse meat for their cats?

Beyond Meat increased its revenues by 250% between 2018 and 2019; consumers are taking an interest in the health and environmental benefits promoted by plant-based foods. Pet owners are showing that they will pay more for luxury and premium pet foods.

Wild Earth is making dog food from cultured fungi proteins and, according to CEO Ryan Bethencourt, revenue is growing steadily even though production is still relatively small.

This plant-based type of cultured pet food, already on the market, is much more expensive than the conventional options. A 18-pound bag of Wild Earth dog food sells for $49 on its website; whereas the website Chewy sells a 18.5-pound bag of Purina Dog Chow for $11.99.

Bethencourt said the potential for cultured protein could be 10% of the total pet food market within the next 10 years. He is using the success of plant-based proteins for humans as evidence for the market potential of alternative pet foods.

Research backs his point; according to one study from 2019, it is clear that an association exists between the diet a pet owner has chosen to follow and the diet they choose to feed their pet.

Culturing microbes into pet food

Another alternative pet food company, Bond Pet Foods, is taking a slightly different approach to cultured pet food. Bond is experimenting with genetically engineering microbes, like yeast.

Theres a lot more that isnt known about growing mice cells to create meat. Theres just a lot more technical challenges that they have to figure out how to ramp up and replicate that kind of meat production, said Rich Kelleman, CEO of Bond Pet Foods.

Bond is using the same approach to genetic engineering used to synthetically produce rennet for cheese production or insulin for diabetics.

What were doing is isolating a skeletal muscle protein so the building blocks of meat and inserting the DNA from that into a microbe, and then using the machinery of the microbe to produce identical animal proteins that you get on a farm and field, drying it down and then using that in a broader recipe to provide high quality nutrition, Kelleman said.

The major pet food companies are also looking for environmentally friendly, alternative proteins that could be inexpensive to scale up as a replacement for conventionally raised meat.

One area were currently exploring is looking at insects as a potential protein source, said Richard Butterwick at the Waltham Institute. They are potentially much more sustainable than traditional mammalian sources of protein and potentially very nutritious, as well.

Venture capital funds are eyeing the potential of cultured alternatives

Last year, Bond completed a $1.2 million seed round of funding and won a $10,000 innovation award from Purina.

Because Animals won this years innovation award and Wild Earth received a $200,000 investment from Mars Petcare during its 2018 investment round. So far, Wild Earth has raised over $16 million from various venture capital funds to pay for its continued growth.

These are relatively small amounts on the scale of the industry, but there is a sense of momentum.

All the big pet food manufacturers are looking at their supply chain and they see challenges with the growth of the pet food market and the population overall, more people means more pets, Kelleman said. Theyre looking for ways that they could mitigate the risk.

Richard Butterwick said that the main concern is that a pets nutritional needs are understood by their owners. He said consumer trends and the humanization of pets should not compromise pet needs, just because there is a trend towards more sustainable eating for humans.

A 2015 study in the Journal of Animal Science looked at the changing attitudes of pet owners choice in food for their companions. The study said it was paramount that sustainability be weighed against animals nutritional demands.

That means conscientious pet owners need to be wary of compromising a pets health just because eating kogi fungus, cricket treats, or lab-grown meats is trending for humans.

Related Stories

If youre a member of your local public radio station, we thank you because your support helps those stations keep programs like Marketplace on the air. But for Marketplace to continue to grow, we need additional investment from those who care most about what we do: superfans like you.

Your donation as little as $5 helps us create more content that matters to you and your community, and to reach more people where they are whether thats radio, podcasts or online.

When you contribute directly to Marketplace, you become a partner in that mission: someone who understands that when we all get smarter, everybody wins.

View original post here:
Pet food makers look to tap the alternative meat market - Marketplace

Read More...

University of Birmingham signs up for strategic research vision in India – University of Birmingham

Tuesday, February 25th, 2020

University of Birmingham Vice-Chancellor Professor Sir David Eastwood with representatives of partner organisations at the signing ceremony in Delhi.

Experts at the University of Birmingham will work with partners in India across education, healthcare, genetic engineering and sports science.

Vice-Chancellor Professor Sir David Eastwood signed a range of Memoranda of Understanding (MoU) with the Universitys partners at a special signing ceremony in Delhi.

The agreements form a key part of the Universitys strategic vision to continue building meaningful education and research partnerships in India.

Professor Sir David Eastwood signed MoUs with:

The University of Birminghams collaborative research output with India partners has almost doubled over the last five years. We currently have over 40 joint research projects of outstanding quality, commented Professor Sir David Eastwood.

We are a global university with a civic heart and a long, illustrious relationship with India. Signing these exciting new agreements with partners in areas such as health, transport and environment gives us a great opportunity to further contribute to Indian society as we continue to forge meaningful research and education partnerships in India.

The University and ICGEB plan to work together on multidisciplinary research including immunity and infection, as well as projects tackling human diseases, compound screening for identifying autophagy modulators, and exchanges of students and staffs across relevant projects.

Working in partnership with CIPLA, University experts will develop healthcare Continuous Professional Development (CPD) programmes.

Researchers at PDPU and Birmingham will continue working on the joint India-H2O project, which is developing, designing and demonstrating high-recovery, low-cost water treatment systems for saline groundwater, as well as domestic and industrial wastewaters. The partners will also identify new research opportunities.

The agreement with Technofin will see the partners working together on a bid to provide rail research and consultancy to the Dedicated Freight Corridor Corporation of India Ltd., to support the establishment of a Heavy Haul Research Institute. They will also develop other infrastructure-related research.

Manipal engineering students will be able to join Birmingham courses in Civil Engineering, Computer Science and Engineering, Electrical and Electronics Engineering, Mechanical Engineering and Mechatronics Engineering - after completing two years of study in India, graduating with degrees from both universities.

University experts will work with Inspire Institute of Sport to develop bespoke distance-learning and blended CPD programmes for the development of the Institutes staff, as well as developing scholarships for postgraduate study in sports science. The MoU is an outcome of the India-UK Sports Alliance set up by the UK Governments Department for International Trade to drive collaboration in sports between the two countries.

Crispin Simon, Her Majestys Trade Commissioner for South Asia, UKs Department of International Trade and British Deputy High Commissioner, Mumbai and West of India, said: I am delighted that the University of Birmingham is strengthening its presence in India across education, healthcare, genetic engineering and sports science. The UK government has played an instrumental role in establishing their partnership with Inspire Institute of Sport, and we will continue to support their work in India.

I am also glad that Professor Tim Cable from the University of Birmingham has made significant contributions to the Indian-UK Sports Alliance organised by the UK government, to bring together influential individuals in both countries to help drive collaboration. I look forward to his continued participation.

See the article here:
University of Birmingham signs up for strategic research vision in India - University of Birmingham

Read More...

More Cell and Gene Therapy Facilities in the Hundreds are Needed – Genetic Engineering & Biotechnology News

Tuesday, February 25th, 2020

The bioindustry will require more cell and gene therapy plants, says an expert, who says the facilities of the future must be automated, scalable, and flexible.

The number of cell and gene therapies entering clinical development has increased significantly in recent years. According to the Alliance for Regenerative Medicines (ARM) there are 1,066 such therapies in trials at present1, which is a 32% increase on the number of studies in 2014. But the surge in clinical activity has not been matched by an increase in production capacity says Darren Dasburg, a cell and gene therapy-focused consultant.

Hundreds of facilities will be needed to manufacture the treatments that are in play now, he said, adding that if you factor in the plants needed to make viral vectors that could exceed a thousand facilities.

The good news, Dasburg says, is that these facilities are more like labs than traditional large biopharmaceutical plants.

Viral vector capacity is critical to the cell and gene therapy sector. Vectors are hollow viruses used to insert genetic material into cells, both cells used in protein expression and cells used therapeutically. Various organisations have voiced concerns about industry capacity to make vectors. In 2018, for example, the Alliance for Advanced Biomedical Engineering said the scarcity of viral vectors could hamper expansion2. Since then the situation has improved, but it has not been resolved3. While viral vector production capacity in the contract services sector has increased, the expansion is still falling short of demand.

Partly this is because of the complexity of making the vectors, according to Dasburg.

Most viral vectors are produced using adherent manufacturing technologies which are expensive to operate, he explains. A vial of just 20 million cells can cost $2030K because it is so challenging to make.

To bring down costs, vector capacity still needs to increase, continues Dasburg, who predicted that biopharma will continue to rely on CDMOs for the foreseeable future.

Cell and gene therapy manufacturing is still a young industry. Biopharma is still figuring out what the ideal production facility should look like.

Building for flexibility and multipurpose manufacturing is important, Dasburg says, noting that explaining CDMOs and IP holders need to understand they are attacking rare genetic diseases and ailments where the therapy might be a third-line treatment. The numbers are often quite lower, and the treatments can be one and done. All meaning the companies of the future will be attacking many more areas of need.

In terms of technology, all cell and gene therapy facilities should feature sufficient isolator capacity, Dasburg says. Isolators are probably the number one investment to make. Too many people are trying to work five people in full dress in a small room attempting to manufacture in a hands-on traditional way when isolation and automation could help immensely.

Dasburg pointed to benchtop platforms capable of processing a single CAR-T patients treatment as an example of an innovative approach being used. These can be arranged in an array within a single ballroom-like facility providing 100% containment going from leukapheresis bag to treatment bag without any human intervention.

References1. alliancerm.org/wp-content/uploads/2020/02/CBX-Meeting-7-Feb-2020-FINAL.pdf2. aabme.asme.org/posts/virus-shortage-for-cell-therapies-creates-engineering-opportunity3. http://www.genengnews.com/insights/gene-therapy-dollar-is-waiting-on-viral-vector-dime/

Link:
More Cell and Gene Therapy Facilities in the Hundreds are Needed - Genetic Engineering & Biotechnology News

Read More...

Viewpoint: We can sustainably feed 10 billion people. Here’s how CRISPR and GMO crops can help – Genetic Literacy Project

Tuesday, February 25th, 2020

Agriculture is responsible for the production of a quarter of the total human-generated greenhouse gases. Growing food also uses about 70 percent of the water available to us. Moreover, agriculture (especially meat production) is the single most significant driver of deforestation and biodiversity loss. Food production is detrimental to the health of the planetbut it doesnt end there. Once the food reaches plates, poor-quality diets cause malnutrition, claiming more lives than tobacco, drug and alcohol combined.

Search for malnutrition online and you will see pictures of frail and sick children. But along with stunting, wasting, vitamin and mineral deficiency, malnutrition also includes overweight, obesity and other diet-related illnesses. Yes, 1 in 9 people around the world go to sleep hungry, but nearly 2 billion adults are also overweight or obese. As such, more than one-third of the world population suffers from at least one form of malnutrition.

With the climate and biodiversity crises, and the global public-health crisis in the form of malnutrition, we must find a healthy and environmentally sustainable diet to feed the growing population. In 2019, the EAT-Lancet Commission brought together leading experts in nutrition, health, sustainability and policy to recommend ways to transform the global food system to achieve a healthy and sustainable diet.

The EAT-Lancet report recommends that planetary health diets to feed 10 billion people by 2050 requires cutting down meat consumption by half and eating twice as much as fruits, vegetables, beans and nuts. Despite recognizing the need to make healthy food affordable for the poor, the EAT-Lancet Commission didnt review the cost and affordability of the ideal diet. Therefore, in a recent global study, scientists reviewed prices for nearly 750 food items to calculate the value of healthy and sustainable diets in 159 countries.

The research, published in Lancet Global Health, shows that many people in low and lower-middle-income countries are too poor to afford EAT-Lancets ideal diet. EAT-Lancet says that we would need to eat twice as much as many fruits and vegetables, and get more protein and fats from plant-source foods. However, the new study found that fruits, vegetables, beans and nuts are the most expensive items of the ideal diet accounting for half of its total price.

Shifting foodsystems

A key challenge of the 21st-century is to change our food system to produce a healthy diet that is both economically and environmentally sustainable. As EAT-Lancets ideal diet isnt affordable for much of the worlds low-income population, authorities must make several parallel interventions to tackle global food inequality.

Lower food prices and higher earnings would give poor people more purchasing power. We must also find cheaper, nutritious food alternatives that are affordable and accessible to people living in low-income areas. I believe that biotechnology has the power to lower the cost of locally and globally grown food, making the ideal diet economically viable to those that need it the most.

One problem is the lack of available, affordable options, which partly stems from decreasing agrobiodiversity. Just three crops (rice, wheat and corn) provide over half of the plant-derived calories worldwide. Shifting calories away from the starchy staple foods towards more nutritious fruits, vegetables and other protein-sourced food remains a significant challenge in meeting EAT-Lancet targets. Grand challenges require great technological solutions, and genetic engineering technology is among the most powerful tools at our disposal.

Power of biotechnology

Biotechnology can improve agrobiodiversity and provide more locally-grown food options for people in low-income areas. One way to do this would be to make inedible plants into a good source of nutrition and calories. Take cottonseed, for example, which has the potential to be a cheaper alternative to nuts. Cottonseeds are highly nutritious, containing oils and proteins in abundance, but many low-income cotton farmers cant eat cottonseeds because they produce toxins called gossypol.

Now, scientists have engineered cotton plants to remove the toxin, making cottonseeds safe for us to eat. And recently, the U.S. Food and Drug Administration approved genetically modified (GM) cottonseed for human consumption. Biotech cottonseed can act as an excellent alternative dietary source in low-income regions, where people struggle to meet the costs of the ideal diet recommended by EAT-Lancet.

Genetic engineering can also enable widespread cultivation of local plants. The groundcherry plant in its native form has a wild, sprawling growth habit which causes its fruits to drop to the ground while still small. Difficulties in cultivating the wildcherry mean its an orphan plant. However, scientists used genetic engineering to improve wildcherrys undesirable traits, including the plants weedy shape, flower production and fruit size. Now there are hopes for large-scale cultivation of genetically engineered groundcherry, which is native to Central and South America.

Millions of children and adults around the world suffer from micronutrient deficiencies, and biotechnology can also help fortify current crops to improve their vitamin and micronutrient contents. For example, scientists have recently developed biofortified cassava, which has higher zinc and iron contents than regular cassava. The biofortified cassava may one day prevent illnesses related to iron and zinc deficiencies.

Golden Rice is perhaps the prime example of a biofortified cropconventional rice that is genetically engineered to produce the vitamin A precursor beta-carotene. Golden Rice, acting as a source of vitamin A, can address vitamin A deficiency that blinds and kills hundreds of thousands of children every year. After a rigorous biosafety assessment in the Philippines, the Department of Agriculture-Bureau of Plant Industry found Golden Rice to be safe as conventional rice. Golden Rice regulation application is under review in Bangladesh, as well. This biofortified crop can provide much-needed micronutrients, taking the everyday staple food further to meet peoples dietary requirements in the poorest regions of the world.

Economic benefits

Improved agrobiodiversity and availability of local food varieties, enabled by biotechnology, will bring down the cost of the ideal diet, reducing food inequality. But GM technology also has the power to lift people out of poverty and increase the spending power of the low-income communities in developing regions.

Higher farm productivity, especially in low-income areas, can lower food prices. A meta-analysis of studies published after 1995 found that adopting GM technology has widespread benefits, including economic gains for farmers that grow GM crops. The meta-analysis found that GM technology increases crop yields by 21 percent. Some GM crops are engineered to be more resistant to pest damage, which helps achieve higher yields, for example.

The meta-study also found that GM crops require 37 percent less pesticide, which reduces pesticide costs by 39 percent and helps spare the environment. Even though GM seeds are more expensive than non-GM seeds, savings in pest control and pesticide use mean that farmers adopting GM crops enjoy 68 percent more profit. Therefore, GM crops can increase farmers spending power, which is excellent news for the quarter of the worlds working population employed in agriculture . More importantly, the yield and profit from GM crops are higher in developing countries than in developed countries.

If adopted widely, genetic engineering technology will bring us closer to meeting the EAT-Lancet dietary targets, which will help us protect the environment, public health, and reduce inequality.

Rupesh Paudyal holds a PhD in plant science and covers agriculture and the environment as a freelance writer. Visit his website and follow him on Twitter @TalkPlant

See more here:
Viewpoint: We can sustainably feed 10 billion people. Here's how CRISPR and GMO crops can help - Genetic Literacy Project

Read More...

Texas coronavirus cases climb to three in San Antonio – The Texas Tribune

Tuesday, February 25th, 2020

Two more cases of the new strain of coronavirus have been confirmed at the San Antonio military base where some evacuees from a cruise ship were quarantined Monday, the Centers of Disease Control and Prevention said at a press conference Friday. This brings the number of confirmed Texas cases of the strain named COVID-19 to three.

The two evacuees were among 329 Americans repatriated against the CDC's recommendation after disembarking from the Diamond Princess off of Japan. Another 16 cruise ship evacuees quarantined in California and Nebraska have also been confirmed to have coronavirus.

"[The passengers] are considered at high risk for infection, and we do expect to see additional confirmed cases of COVID-19 among the passengers," said Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases, during the press conference.

There are also several Americans hospitalized in Japan who are "seriously ill," she said.

The first Texas case was confirmed Feb. 13 when one of 91 Americans evacuated from the Hubei province of China, the epicenter of the outbreak, was hospitalized. The remaining 90 Americans were released from the San Antonio base Thursday because they showed no symptoms after a 14-day quarantine.

The World Health Organization declared COVID-19 a public health emergency by last month. According to the latest CDC report, there are over 75,000 confirmed cases worldwide, and the death toll has surpassed 2,000. But outside of China, there have been only three fatalities, and none in the U.S.

The total number of confirmed U.S. cases is 34. However, the CDC makes a distinction between cases among repatriated Americans and all other U.S. cases, as the former aren't an accurate representation of how the virus is spreading within the country, according to Messonnier.

"We don't yet have a vaccine for this novel virus, nor do we have a medicine to treat it specifically," Messonnier said.

The goal now is to slow the introduction of the virus into the U.S. to buy time to prepare the community for more cases and possibly sustained spread, she added.

Two elderly Japanese passengers aboard the Diamond Princess died after testing positive for the virus, Japan's health minister said Thursday.

Researchers at the University of Texas at Austin are working on a vaccine, and a Houston-based genetic engineering company announced this week it finished developing one. However, the Food and Drug Administration has not yet approved a vaccine.

Disclosure: The University of Texas at Austin has been a financial supporter of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here.

Link:
Texas coronavirus cases climb to three in San Antonio - The Texas Tribune

Read More...

Confused About Obesity, Supplements and Organic Food? Here’s A Handbook For Busting Nutrition Myths – American Council on Science and Health

Tuesday, February 25th, 2020

The internet can be a confusing place. A five-minute Google search for nutrition advice is perhaps the best illustration of this fact. Allow me to demonstrate with a classic example. Do GMO crops cause cancer?

Most GMOs are designed to be sprayed with Monsantos Roundup herbicide Glyphosate, the active ingredient in Roundup, is classified as a class 2A carcinogen by the International Agency for Research on Cancer ...

Or this:

Science has been studying cancer for a long time, and it has come to a few conclusions. One of which is that there are precious few ways to prevent cancer, and avoiding GMOs is not one of them.

The first statement was written by an anti-biotechnology activist with a history of fabricating fears about genetic engineering, the second by a biochemist with 30 years of research experience. Nonetheless, the average consumer or athlete may not know whom to believe at first glance. Faced with this contradictory but seemingly authoritative commentary, what do you do if you really want to know if GMOs boost your cancer risk?

The solution is simple, if not always easy to apply: turn to the experts and think critically about everything you read. To make that task a bit easier in practice, nutrition scientist David Lightsey has produced a helpful handbook to guide curious consumers through the morass dietary nonsense they'll inevitably encounter online: The Myths About Nutrition Science (TMNS).

A food and nutrition science advisor to QuackWatch, Lightsey has spent 31 years separating evidence-based information from plain old nonsense. His book, at just over 200 pages, will arm readers with a basic understanding of many perennially important nutritional issueseverything from obesity and supplements to GMO crops and pesticidesand a useful immunization against the junk science peddled online, what Lightsey calls the quagmire of misinformation which is so pervasive in this area.

This book would have been enormously helpful to me as a budding science journalist a decade ago, but anybody looking for sound nutrition information will get something out of TMNS.

The useless media and health news

Arguably the best part of TMNS is its takedown of mainstream health reporting. Citing the now classic 2005 study by physician John Ioannidis, Lightsey begins by pointing out that the bulk of medical research published today is simply incorrect. Eager to publish flashy results in top-tier science journals and desperate for grants (the lifeblood of any working scientist), many academics have resorted to cutting corners to get the results they know will attract attention, and thus more research funding.

If bona fide experts get so much wrong, Lightsey asks, can a journalist with little or no science background accurately assess what he or she is reporting on? The answer is usually no, unfortunately. Reporters don't have to be crippled by scientific illiteracy; a dedicated journalist can correct their knowledge deficit by doing some homework before writing a story. The real problem is, few of them do.

Instead, reporters more or less copy their stories from press releases universities distribute to promote research conducted by their faculty. Lightsey cites a 2015 study, for instance, which found that just over 85% of 312 medical news stories were derived from a press release or some other secondary source.

This is sloppy reporting, pure and simple. But science by press release has more lasting consequences: it exaggerates a study's results and fails to contextualize them among the much larger body of research on the topic in question. This is one of the primary reasons ACSH has caught just about every mainstream media network irresponsibly reporting, for example, that 95% of baby food is contaminated with heavy metals.

Misinformation is everywhere

This is a recurring theme throughout Lightsey's book. Whether it's a mainstream reporter, a supplement salesman at the gym or a celebrity athlete, nobody's entitled to our trust when it comes to nutrition. That's not because these sources of information are inherently unreliable, although they often do peddle nonsense. The real reason is that informed consumers should make decisions that comport with the available evidence, and not based on the conclusions of a single study or the recommendations of Tom Bradyno matter how many Super Bowls he's won.

Returning to our opening point above, Lightsey pithily sums things up:

Nutrition 'science' has become so contradictory that one must learn to take every new 'study' which declares to enlighten us about some purported nutritional health threat or benefit with a large grain of salt.

Excerpt from:
Confused About Obesity, Supplements and Organic Food? Here's A Handbook For Busting Nutrition Myths - American Council on Science and Health

Read More...

Protein Expression Market size, leaders, segment analysis and future scope scrutinized in the new analysis – WhaTech Technology and Markets News

Tuesday, February 25th, 2020

North America has been the largest market for protein expression, with the U.S. as the larger contributor to the regional market as compared to Canada.

The protein expression market valued at $1.4 billion in 2016, and during the forecast period, it is expected to grow at an 11.7% CAGR, generating revenue of $3.0 billion by 2023. The key drivers of the market are technological advancements, growing life sciences sector, and increasing chronic disease prevalence, funding for protein-based research, and geriatric population.

Protein expression is a collective term for ways in which proteins are synthesized, modified, and regulated in living organisms.

Download sample copy of this report at@bit.ly/38YmQAq

A prominent trend in the protein expression marketis the increasing research and development (R&D) activities on recombinant proteins. The technologies that are used to produce recombinant proteins, such as gene cloning and genetic engineering, have revolutionized the life sciences sector and enabled the production of biopharmaceuticals at an industrial scale.

Their production on such a large scale has led to their application in disease diagnosis and treatment. Many pharmaceutical companies are focusing on the production of recombinant proteins and their expression systems to support the drug discovery process and develop biotherapeutics.

The protein expression market is segmented by region, system, end user, product and services, and application.

Based on system, the categories are algal-based, prokaryotic, cell-free, mammalian cell, yeast, and insect cell expression systems. In 2016, prokaryotic expression systems registered the largest share as they are comparatively cheaper than other expression systems, such as insect cell and mammalian systems.

In addition, the shorter protein synthesis time of the prokaryotic expression system, as the bacteria multiply and grow rapidly in these systems, giving a higher yield, promotes their adoption.

Pre-AccessInquiry at@bit.ly/2SVOV5E

North America, Middle East & Africa, Europe, Latin America, and Asia-Pacific (APAC) are the subdivisions of the region segment of the protein expression market. In 2016, the market was dominated by North America, followed by Europe.

Even though during the forecast period, the market is expected to be led by North America, the fastest growing market would be APAC. This may be attributed to the increasing geriatric population, rising R&D funds, improving per capita income, and rising prevalence of chronic diseases in the region.

Therefore, the market for protein expression is set to experience remarkable growth during the forecast period owing to an increase in drug discovery and development and growing prevalence of several types of diseases.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more here:
Protein Expression Market size, leaders, segment analysis and future scope scrutinized in the new analysis - WhaTech Technology and Markets News

Read More...

Healthy-ish French Fries Are Now a Thing Thanks to Genetic Redesigning – Observer

Tuesday, February 25th, 2020

With Calyxt making fried foods healthier, maybe celebs will actually eat them instead of just posing with them. Rich Polk/Getty Images for The Weinstein Company

Eat up, America. Your favorite standby comfort foodthose slightly greasy, salted-just-right French fries that have thrown many a dieter off the straight and narroware now healthy. Or at least healthier than they ever have been, thanks to food-tech disruptor Calyxt (pronounced Kay-Lix with an aspirated t at the end) and its breakout vegetable oil, which is designed with less saturated fat and more healthy oleic acid than typical unmodified frying oils.

I first stumbled across Calyxts healthy frying oil at the most unlikely of places: the Minnesota State Fair,a 320-acre mecca of unhealthy eating, butter sculptures, live farm animal births and other assorted curiosities.

SEE ALSO: How Blue Apron Became a Massive $2 Billion Disaster

Any good Minnesotan worth his weight in walleye, even those of us like me who have lived all over the world, will always make a point to come back to our native Land of 10,000 Lakes in late August, in part so we can take in one of the states few months of non-sub-zero temperatures, but also because the second half of August is precisely when we can visit the two-week affair known among locals as the The Great Minnesota Get-Together. Its the largest of its kind in the country, and last years attendance drew in over two million visitors, meaning over a third of all Minnesotans took a day out of their lives to join in on the perennial celebration.

At last years gathering, word was spreading quickly that the Ball Park Caf, a long-time state fair staple, known for its famous beer selection, burgers and garlic fries, had switched to Calyxts healthier vegetable oil for all of its frying needs. Given that the fair happened to fall just as I was several weeks into one of my many concerted efforts to finally get back in shape, I was intrigued.

I was expecting the fries I ordered to taste somehow artificial or rubbery, as do many healthy versions of other foods, but the flavor and consistency of the Calyxt-fried Freedom Fries was exactly as one might expect from a normal bath of hot oilcrispy and yummy. Decadence never tasted so good.

Several weeks after the fair, I looked up the company behind this healthy oil and scheduled a meeting with Calyxts communications head, Trina Lundblad and company CEO Jim Blome. We decided to meet at their offices, a sleek, ultra-modern building in a Minneapolis suburb, overlooking a large swath of prairie grass and pristine crop rows.

The Calyxt headquarters have a definite Silicon Valley feel. Were not an ag company; were a tech company that is applying its IP to the ag sector, said company spokeswoman and communications head Trina Lundblad. Courtesy of Calyxt

For the next several hours that I spent touring the Calyxt headquarters, I came to realize that I was not just visiting, contrary to my expectations going in, another food-based CPG company simply riding the wave of a popular new frying oil with a healthy twistI was at ground zero of the tech revolution in agriculture, where genome editing is revolutionizing the nutritional attributes of the foods we, as humans, will need to continue as a species in the years and centuries to come.

If that sounds like a big deal, its because it is.

Calyxt describes its oil, the product of an improved soybean plant, as having the heart-healthy fat profile of olive oil without the distinctively earthy aftertaste that is fine for spaghetti, but less so for waffles or fried chicken. By using a breakthrough gene-editing technology, Calyxt is engineering an entirely new set of processes for improving the genetic profile for many staples of the nutritional supply chain without introducing transgenic, foreign properties into the mix; Calyxts technology stands out in that it is simply accelerating and improving upon what nature would have probably gotten around to eventually on its own, only several millennia later.

Importantly, the process used by Calyxt, which relies on DNA-cutting enzymes that thankfully go by the abbreviation TALEN (transcription activator-like effector nuclease), sidesteps much of the public and regulatory outcry often associated with traditional GMOs (genetically modified organisms), in which an organisms genetic makeup has been modified in a laboratory using transgenic technology that combines, in a sort of Frankenstein-esque way, plant, animal, bacterial and virus genes that do not occur in nature or through traditional crossbreeding methods.

Calyx, which is a publicly-traded company on the NASDAQ, is improving upon the farm to table fever, by starting upstream.

Way upstream.

Calyxts unique engineering process begins in the high-tech labs on the top floor of the companys headquarters, where a team of scientists reconfigure gene molecules on large computer monitor screens before instructing robotically controlled laboratory pipettes to do their thing. Later, embryonic plant cells are transferred to petri dishes that deliver the customized TALENs, which are then bathed in stimulating hormones and left to grow until they become big enough to see if the edits made upstream in the top floor lab were successful.

Plants that meet the designer teams original specs get pampered in high-tech temperature-regulated nurseries before later graduating to a greenhouse or to the small outdoors plot trials that abut the Calyxt headquarters. From the top performing plants, Calyxt begins developing seed banks that will eventually be sold to farmers.

But that is only the beginning. Its here, at this leg of the business, where Calyxt is positioning itself for long-term, paradigm shifting growth at the crossroads of technology and agriculture.

Jim Blome, the CEO of Calyxt, grew up in a family farm in central Iowa. Today, he leads a company that is playing a major role in defining the future of food on a global scale. Courtesy of Calyxt

Unlike most biotech companies that play in the broader competitive landscape of gene-editing, Calyxt is unique in that it is vertically integrating, contracting with farmers across the Midwest to grow its gene-edited, high oleic soybeans. Earlier this month, the company achieved an important milestone, having successively contracted 100,000 soybean acres with U.S. farmers, more than doubling the size of its planted acres from the previous year. Calyxt CEO Jim Blome lauded the achievement stating that 100,000 contracted acres will support market demand for our high oleic soybean oil.

Calyxts scientists design gene-editing molecules on computer screens, then use robots to build them using a set of DNA-cutting enzymes called TALENs, which are later transferred to petri dishes for analysis. Courtesy of Calyxt

After the growing season, just a few weeks after the Minnesota State Fair wraps up, Calyxt exercises its contracts to buy back the beans from the farmers at a premium to market prices and crushes them to make its healthy, french fry-friendly oil, which it is currently shipping across the country to food services companies and restaurant chains.

Farmers love the higher-than-market commodities prices Calyxt agrees to pay them. The food services sector loves the healthy aspects of the Calyxt end-product, which also has a reuse rate far more efficient than other oils on the market. And Calyxt loves sitting in the middle of both the supply and distribution chains.

I have spent my life in agriculture, and there is nothing as revolutionary happening around genome editing as what we are doing at Calyxt, added Blome, who previously served as the president and CEO of the North American Crop Science division of Bayer, the German multinational pharmaceutical and life sciences juggernaut. We are developing a foundation for the future of global agriculture through precision plant breeding and advanced analytical tools to solve complex challenges with system-based approaches. Tillable land is growing increasingly scarce, populations are growing and the earth is warming, and frankly, we arent ready for what this will mean even five or 10 years down the road.

What we are doing at Calyxt is harnessing the technology that will enable the entire global nutritional and industrial supply chain to adapt to these seismic changes underfoot. And were doing it in a responsible, ethical manner, that brings new opportunities to U.S. farmers, added Blome.

The Calyxt chief isnt simply talking about healthier frying oils, there is a much, much bigger play in the offing: Calyxts technology can be harnessed to address some of the most pressing concerns across all of food and nutritionfrom removing the allergens from nuts and peanuts, to designing better cereal plants, such as wheat, that not only deliver better yields but also address common allergies and afflictions like gluten intolerance. Tubers, tree fruits, CBD productsthe list of potential applications for Calyxt genome-editing is nearly endless.

Where high-tech meets agriculture. Calyxt researchers and plant scientists use state-of-the-art aeroponics growing facilities to iterate on plant-based genome editing. Courtesy of Calyxt

Chris Neugent, a veteran food marketer and former CEO of Post Consumer Brands, the maker of everything from Oreo Os to Grape-Nuts, sits on the board of Calyxt, bringing mission-critical consumer marketing and story-telling gravitas to a company known best for its high-tech bioengineering.

If the Calyxt story was a book, then you could say we are still in the first chapter, probably still on page one. Our work with smarter, healthier soybean oilsas groundbreaking as it isis still proof of concept. As we scale our business and begin adding more products, the market will begin to see us not as the healthier french fry guys but as a company that is revolutionizing next-generation nutrition in agriculture, observed Neugent. We are literally laying track for the biggest agricultural revolution since the transformation of human societies from hunting and gathering to farming. Its that big.

This Second Agricultural Revolution Neugent is alluding to envisages a not-so-far-off future in which Calyxt is redesigning crops to better withstand the massive changes underfoot caused by global warming, over-population and other seismic shifts affecting the future of food.

A young soybean plant flowers inside the Calyxt high-tech laboratory facilty. Courtesy of Calyxt

Like any industry that is shaking up the status quo, Calyxt is beginning to encounter its share of crosscurrents. So far, at least, U.S. regulators seem to be of the opinion that as long as Calyxt is making genetic alterations that could have conceivably occurred naturally, as opposed to other transgenic techniques used in GMOs, no special regulation is needed.

Other incumbent seed engineering companies have dabbled in the high oleic soybean space, but for the most part, they have come at the challenge through a more conventional gene-editing approach, which mixes in organisms that do not naturally conjoin outside of a laboratory, necessitating additional layers of regulatory safeguards.

Calyxt is using high-tech genome editing to serve up healthier versions of the same delicious plant-based foods that we have eaten for decades. Courtesy of Calyxt

For now, Calyxts approach doesnt require any additional oversight or specific product labeling, nor do company executives feel that any will be required at any point in the foreseeable future. The 2018 USDA-released GMO labeling requirements defines bioengineered foods as those containing detectable genetic material that has been modified through lab techniques that cannot be created through conventional breeding or found in nature. As a result, Calyxt is not subject to any additional regulatory or labeling requirements, which is allowing the company to forge ahead on multiple fronts. The company is already engaged in early experimentation with genome edited wheat plants, and it has scores of other applications in development.

For now, Calyxt is a still a small company, but one poised to make a big impact on the global food market.

However, for most of usat least those of us that just like to be able eat French fries from time to time and not feel too bad about it the next dayCalyxt is performing an equally important service on par with helping prepare global food sourcing for the impacts of climate change; they are giving us peace of mind the next time we hit the state fair, or anywhere else where Calyxt-fried French fries are being served.

See original here:
Healthy-ish French Fries Are Now a Thing Thanks to Genetic Redesigning - Observer

Read More...

Page 8«..78910..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick